The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)

The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.

Habte Yimer, MD, discussed the findings from the phase 3 ALPINE trial and explored how these results are shaping clinical decisions in chronic lymphocytic leukemia treatment.

BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

When given in combination, sonrotoclax and zanubrutinib shows promise in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, according to data from the BGB-11417-101 study.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discussed the real-world effectiveness of brexu-cel for relapsed/refractory B-cell acute lymphocytic leukemia.

Findings from the phase 3 E1910 study showed that blinatumomab extended overall survival when added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia.